How DNA damage affects treatment resistance in brain cancer
Epigenetic alterations after DNA damage repair drive treatment resistance in glioblastoma
['FUNDING_CAREER'] · UNIVERSITY OF SOUTHERN CALIFORNIA · NIH-10917379
This study is looking at how changes in DNA after damage can affect how genes work in glioblastoma, a tough brain tumor to treat, and it aims to help researchers understand why some treatments don’t work as well as they should.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTHERN CALIFORNIA (nih funded) |
| Locations | 1 site (Los Angeles, UNITED STATES) |
| Trial ID | NIH-10917379 on ClinicalTrials.gov |
What this research studies
This research investigates how changes in DNA methylation after DNA damage can influence the organization of chromatin and gene regulation in glioblastoma, a challenging brain tumor to treat. By using patient-derived glioblastoma cell cultures, the study aims to understand the mechanisms behind treatment resistance that arise from these epigenetic alterations. The principal investigator will also receive training and mentorship to enhance their skills and knowledge in this area, contributing to their development as an independent researcher.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who are experiencing treatment resistance.
Not a fit: Patients with other types of brain tumors or those not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming treatment resistance in glioblastoma patients.
How similar studies have performed: Previous research has shown that understanding epigenetic changes can lead to breakthroughs in cancer treatment, suggesting that this approach has potential for success.
Where this research is happening
Los Angeles, UNITED STATES
- UNIVERSITY OF SOUTHERN CALIFORNIA — Los Angeles, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MODREK, ARAM SANDALDJIAN — UNIVERSITY OF SOUTHERN CALIFORNIA
- Study coordinator: MODREK, ARAM SANDALDJIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer